Abstract:Background: Mutations in DNA Damage Response (DDR) genes, including those resulting in loss of Ataxia-Telangiectasia, Mutated (ATM) expression are common in advanced prostate cancers (PC). Poly (ADP-ribose) polymerase (PARP) inhibitors are approved in this setting but demonstrate limited clinical efficacy in ATM-mutant PCs. In this project, we sought to define the impact of ATM loss on DDR pathways in PC, with the goal of identifying alternate therapeutic vulnerabilities. Methods: ATM-KO PC cell lines were generated via CRISPR-Cas9. ATM loss and attenuation of downstream kinase activity were confirmed via western blot. Phosphoproteomic evaluation in parental and ATM-KO cells was performed following ionizing radiation (IR). Clonogenic survival assays were performed after treatment with inhibitors and/or IR. Kinetics of DDR foci recruitment and resolution were interrogated with immunofluorescence (IF). DNA fiber assays were utilized to assess replication stress. Results: ATM-KO PC cells were able to effectively repair DNA damage following IR, as measured by resolution of yH2ax, 53BP1, and MDC1 foci. Phosphoproteomic studies indicated that ATM-KO cells maintained canonical DDR pathways through activation of ATR and DNA-PKcs kinases. Treatment of ATM-KO cells with either the ATR inhibitor VX970 or the DNA-PKcs inhibitor M3814 incrementally affected DDR in ATM-KO cells compared to ATM-proficient parental control cells. Importantly, combination treatment with VX970 and M3814 was needed to prevent downstream DDR foci recruitment in ATM-KO cells and was more effective in radiosensitizing ATM-KO PC than either parental control cells or single drug treatment. These data indicate that the activity of any one of the trinities of these kinases is sufficient to mediate DDR and that blockade of both ATR and DNA-PKcs is needed to effectively prevent DDR in ATM-KO PC. Further, DNA fiber assays showed significantly decreased fork length with dual treatment compared to control or single drug, indicating increased replication stress. We then leveraged a RUVBL1 ATPase inhibitor Compound B, which affects the expression of these three kinases. In ATM-KO PC cells, Compound B attenuated ATR and DNA-PKcs expression and radiosensitized the cells as shown by clonogenic survival assays. DNA fiber assays indicated that Compound B induced replication stress in ATM-KO PC cells to the same extent as combination therapy. In combination with IR, Compound B also significantly attenuated the growth of ATM-KO PC xenografts in vivo. Conclusions: Our unbiased phosphoproteomic approach indicated that ATR and DNA-PKCs mediate DDR following IR in ATM-KO PC cells, and that dual targeting of both ATR and DNA-PKcs is necessary to block DDR in ATM-KO PC cells. We have identified that Compound B effectively depletes ATR and DNA-PKcs, sensitizes to DNA damage, and induces replication stress in ATM-KO PCs. Our studies suggest that Compound B may be a novel therapeutic strategy in ATM-mutant PC. Citation Format: Mia E. Hofstad, Lan Yu, Andrea Woods, Zoi E. Sychev, Alice Mazzagatti, Xiaofang Huo, Ralf Kittler, Peter Ly, Justin M. Drake, Ganesh V. Raj. Deciphering DNA damage repair in ATM mutant prostate cancers [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: DNA Damage Repair: From Basic Science to Future Clinical Application; 2024 Jan 9-11; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2024;84(1 Suppl) nr A020.

Targeted Mass Spectrometry Enables Quantification of Novel Pharmacodynamic Biomarkers of ATM Kinase Inhibition

Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM

Development of Pharmacodynamic Biomarkers for ATR Inhibitors

Computational Analysis of Non-synonymous SNPs in ATM Kinase: Structural Insights, Functional Implications, and Inhibitor Discovery

Discovery of novel ataxia telangiectasia mutated (ATM) kinase modulators: Computational simulation, biological evaluation and cancer combinational chemotherapy study

Ataxia-Telangiectasia Mutated (ATM) loss of function displays variant and tissue-specific differences across tumor types

Small Molecular Inhibitors That Target ATM for Drug Discovery: Current Research and Potential Prospective

Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types

ATM-SPARK: A GFP phase separation–based activity reporter of ATM

Targeting the ATM pathway in cancer: Opportunities, challenges and personalized therapeutic strategies

Abstract A020: Deciphering DNA damage repair in ATM mutant prostate cancers

Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining

Abstract 2143: Clinicopathologic, genomic and immunophenotypic landscape of ATM mutations in non-small cell lung cancer

Chemo-phosphoproteomic profiling with ATR inhibitors berzosertib and gartisertib uncovers new biomarkers and DNA damage response regulators

Abstract 2405: Delineating molecular vulnerabilities of ATM mutant prostate cancers

ATM Inhibition Induces Synthetic Lethality and Enhances Sensitivity of PTEN-deficient Breast Cancer Cells to Cisplatin.

Abstract 5130: Phospho-proteomic dynamics reveal DNA damage and repair signatures of drug sensitivity

Discovery of [1,2,3]Triazolo[4,5-C]quinoline Derivatives As a New Class of Ataxia-Telangiectasia Mutated Kinase Inhibitors

Progress of ATM Inhibitors: Opportunities and Challenges

Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer

Regulation of ATM in DNA Double Strand Break Repair Accounts for the Radiosensitivity in Human Cells Exposed to High Linear Energy Transfer Ionizing Radiation.